Name (Synonyms) | Correlation | |
---|---|---|
drug1825 | Placebo (Plasma-Lyte 148) Wiki | 1.00 |
drug906 | FAVICOVIR 200 mg Film Tablet Wiki | 1.00 |
drug1080 | Human umbilical cord derived CD362 enriched MSCs Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D013577 | Syndrome NIH | 0.11 |
D055371 | Acute Lung Injury NIH | 0.10 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.10 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.09 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
A single dose of Reference product containing 200 mg favipiravir and a single dose of Test product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at room temperature, in each period under fasting conditions with current pandemic precautions.
Description: Area under the concentration-time curve of favipiravir in plasma over the time interval from 0 to 24 hours
Measure: AUC0-tlast of Favipiravir Time: 0 to 24 hours post-doseDescription: Maximum plasma concentration of favipiravir
Measure: Cmax of Favipiravir Time: 0 to 24 hours post-doseDescription: Area under the plasma concentration curve to infinite time of favipiravir
Measure: AUC0-inf of Favipiravir Time: 0 to 24 hours post-doseDescription: Time to reach maximum plasma concentration of favipiravir
Measure: Tmax of Favipiravir Time: 0 to 24 hours post-dose